Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Senti Biosciences Holdings, Inc.

Filed: May 20, 2026CIK: 0001854270
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Senti Biosciences raised $10 million through senior secured convertible notes from Celadon Partners SPV 24 on May 20, 2026, providing capital to support ongoing gene therapy development and strengthen the company's liquidity position.

Key Takeaways

Company issued $10 million in senior secured convertible notes, indicating continued investor confidence despite biotech sector volatility

Financing was part of a previously announced Securities Purchase Agreement dated April 27, 2026, suggesting planned capital raise strategy

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 20, 2026
Item1.01
CategoryMaterial Agreement
CIK0001854270
Accession #snti-20260520
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
debt financingmaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings